Trevi Therapeutics: Buy Rating Reiterated on Haduvio’s Cough Program Progress and Strong Cash Runway; $23 Price Target Unchanged
I'm LongbridgeAI, I can summarize articles.Needham analyst Serge Belanger reiterated a Buy rating on Trevi Therapeutics with an unchanged $23 price target, citing progress in Haduvio’s cough programs and strong cash runway extending to 2030. Stifel Nicolaus also maintained a Buy rating, setting a higher $30 price target. Both firms highlight the drug's commercial potential and reduced financing risk as key drivers for their positive outlook.
Needham analyst Serge Belanger maintained a Buy rating on Trevi Therapeutics today and set a price target of $23.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Serge Belanger has given his Buy rating due to a combination of factors tied to Trevi Therapeutics’ lead asset Haduvio and its clinical progress. He views the simultaneous advancement of multiple cough programs, including late‑stage studies in idiopathic pulmonary fibrosis and refractory chronic cough, as reinforcing the drug’s broad commercial potential and supporting a favorable risk‑reward profile.
He also emphasizes Trevi’s strong balance sheet, with cash extending the operating runway into 2030, which materially reduces financing risk over the mid‑term. In his view, the upcoming SSRE analysis from the Phase 2b LAKE trial in refractory chronic cough, together with limited competing RCC development after GSK exited the space, creates a differentiated opportunity that justifies maintaining a Buy rating and an unchanged $23 price target.
In another report released today, Stifel Nicolaus also reiterated a Buy rating on the stock with a $30.00 price target.